Ten years of screening for congenital disorders of glycosylation in Argentina: Case studies and pitfalls

Background: Congenital Disorders of Glycosylation (CDG) are genetic diseases caused by hypoglycosylation of glycoproteins and glycolipids. Most CDG are multisystem disorders with mild to severe involvement. Methods: We studied 554 patients (2007–2017) with a clinical phenotype compatible with a CDG....

Full description

Bibliographic Details
Authors: Asteggiano, Carla Gabriela, Papazoglu, Gabriela Magali, Bistue Millon, Maria Beatriz, Peralta, Maria Fernanda, Azar, Nydia Beatríz, Spécola, Norma, Guelbert, Norberto Bernardo, Suldrup, Niels, Pereyra, Marcela, Dodelson de Kremer, Raquel
Format: article
Status:Published version
Publication Date:2018
Country:Argentina
Institution:Consejo Nacional de Investigaciones Científicas y Técnicas
Repository:CONICET Digital (CONICET)
Language:English
OAI Identifier:oai:ri.conicet.gov.ar:11336/164486
Online Access:http://hdl.handle.net/11336/164486
Access Level:Open access
Keyword:CDG
Glycosilation
IEF
NGS
https://purl.org/becyt/ford/1.6
https://purl.org/becyt/ford/1
Description
Summary:Background: Congenital Disorders of Glycosylation (CDG) are genetic diseases caused by hypoglycosylation of glycoproteins and glycolipids. Most CDG are multisystem disorders with mild to severe involvement. Methods: We studied 554 patients (2007–2017) with a clinical phenotype compatible with a CDG. Screening was performed by serum transferrin isoelectric focusing. The diagnosis was confirmed by genetic testing (Sanger or exome sequencing). Results: A confirmed abnormal pattern was found in nine patients. Seven patients showed a type 1 pattern: four with PMM2-CDG, two with ALG2-CDG, and one with classical galactosemia. A type 2 pattern was found in two patients: one with a CDG-IIx and one with a transferrin protein variant. Abnormal transferrin pattern were observed in a patient with a myopathy due to a COL6A2 gene variant. Conclusions: CDG screening in Argentina from 2007 to 2017 revealed 4 PMM2-CDG patients, 2 ALG2-CDG patients with a novel homozygous gene variant and 1 CDG-IIx.